mecamylamine has been researched along with Parkinson Disease in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with nicotine, dose-dependently blocked this toxicity." | 1.38 | Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease. ( Caviedes, P; Cuevas, C; Huenchuguala, S; Muñoz, P; Paris, I; Segura-Aguilar, J; Tizabi, Y; Villa, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muñoz, P | 1 |
| Huenchuguala, S | 1 |
| Paris, I | 1 |
| Cuevas, C | 1 |
| Villa, M | 1 |
| Caviedes, P | 1 |
| Segura-Aguilar, J | 1 |
| Tizabi, Y | 1 |
1 other study available for mecamylamine and Parkinson Disease
| Article | Year |
|---|---|
Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease.
Topics: Animals; Cell Line; Dicumarol; Dopaminergic Neurons; Dose-Response Relationship, Drug; Indolequinone | 2012 |